Trials / Unknown
UnknownNCT00252044
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Bronx VA Medical Center · Federal
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1) working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis by drug administration of 0.3 mg of oral pergolide interaction for performance on the cognitive tasks, with the schizotypal personality disorder group demonstrating significantly improved peformance compared to the other personality disorder group after pergolide compared with placebo. Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed by pergolide for four weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pergolide |
Timeline
- Start date
- 2000-10-01
- First posted
- 2005-11-11
- Last updated
- 2005-11-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00252044. Inclusion in this directory is not an endorsement.